News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 10, 2022BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter...
- Nov 7, 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update...
- Nov 7, 2022
New post-hoc analyses that account for ALSFRS-R floor effects add to the robust body of evidence supporting a clinically meaningful treatment effect with NurOwn® in ALS NEW YORK, Nov. 7, 2022...
- Oct 20, 2022
Biomarker analyses show robust increases in cerebrospinal fluid neuroprotective biomarkers following NurOwn treatment NEW YORK, Oct. 20, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc....
Oct 7, 2022NurOwn® drove biomarker responses, affecting pathways related to neurodegeneration, neuroinflammation, and neuroprotection, that were consistent in participants with both advanced ALS and less...